ClinicalTrials.gg
RecruitingNCT07203625OPTION-2Updated Mar 19, 2026

Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours

A Phase 4 interventional study of Tenecteplase thrombolysis in Acute Ischemic Stroke and Basilar Artery Occlusion, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Xuanwu Hospital, Beijing · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing tenecteplase in Ischemic Stroke — 32 open to participants now, 32 under way, 25 of them phase 3. Tenecteplase · Ischemic Stroke.

Planned enrollment
38th of 59
316 · median 466
Started
2026
with 10 others
Phase 4
5 of 59
4 open now
Primary completion
2027-12
later than 13 of 31 live
Registered
46th of 59
by date
Lead sponsor
4 of 59
Xuanwu Hospital, Beijing

Among the 59 studies testing tenecteplase in Ischemic Stroke, this one is the 38th largest by planned enrollment, is one of 11 that started in 2026, is one of 5 in phase 4, reaches primary completion later than 13 of the 31 other live ones, and was the 46th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

32 of the 59 studies testing tenecteplase in Ischemic Stroke are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About tenecteplase

Tenecteplase: first FDA approval 2000 (TNKASE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing tenecteplase in Ischemic Stroke, or all of them as a file.
02

Study summary

This study is designed to investigate the efficacy and safety of intravenous tenecteplase before interhospital transfer from a non-endovascular capable center(nECC) to an endovascular capable center (ECC) for thrombectomy in patients with acute ischemic stroke (AIS) caused by neuroimaging-confirmed acute basilar artery occlusion (BAO) between 4.5-24 hours of symptom onset.

Read the detailed description

This is a multicenter, prospective, open-label, blinded endpoint (PROBE), randomized controlled trial in patients with acute ischemic stroke due to BAO first presenting to a nECC and intending to undertake thrombectomy in an ECC.

Patients will be required to have occlusion of the basilar artery on baseline computed tomography angiography (CTA)/magnetic resonance angiography (MRA) at the nECC. Patients will be randomized to either intravenous tenecteplase (0.25mg/kg, maximum 25mg)or not before interhospital transfer.

03

Conditions studied

  • Acute Ischemic Stroke
  • Basilar Artery Occlusion

Browse trials for

Keywords

  • basilar artery occlusion
  • thrombolysis
  • interhospital transfer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years;
  • Patients presenting with posterior circulation ischemic stroke symptoms due to BAO;
  • BAO confirmed by computed tomographic angiography (CTA)/ magnetic resonance angiography (MRA);
  • Time from AIS symptom onset to randomization within 4.5-24 hours, stroke onset is defined as the onset of acute symptoms leading to the clinical diagnosis of basilar artery occlusion (BAO) not considering the time of any preceding minor prodromal symptoms (such as isolated vertigo, diplopia or sensory changes) as onset time or, if not known, the time the patient was last known to be well (including wake-up stroke and unwitnessed stroke);
  • Baseline National Institute of Health Stroke Scale (NIHSS) score obtained prior to randomization ≥6;
  • Functionally independent (modified Rankin Scale [mRS] 0-2) prior to stroke onset;
  • Intended to transfer for thrombectomy. Two paradigms are allowed in this study: (1)transferring patients to ECC (patient transfer); (2)travelling neurointerventionist to nECC (physician transfer);
  • Written from patients or legally responsible representatives

Exclusion criteria

Exclusion Criteria:

  • Posterior Circulation Acute Stroke Prognosis Early CT score (PC-ASPECTS) \< 6 on computed tomography (CT)/CTA-Source Images/MRI with diffusion-weighted imaging (DWI)
  • CT/MR shows evidence of intracranial hemorrhage and tumor (except small meningioma)
  • Complete cerebellar infarct on CT/MRI with significant mass effect and compression of the 4th ventricle
  • Bilateral extensive brainstem infarction on CT/MRI
  • Simultaneous occlusion of both anterior and posterior circulation confirmed by CTA/MRA/DSA (patients with a history of occlusion of anterior circulation more than three months ago can be included)
  • Treatment with a thrombolytic within the last 72 hours or intention to receive intravenous thrombolysis
  • Known or allergy to any ingredients of Tenecteplase
  • Any other for intravenous thrombolysis except for the time criteria
  • Known hereditary or acquired hemorrhagic diathesis
  • Impairment in coagulation due to comorbid disease or anticoagulant use. If on warfarin, (INR) >1.7 or prothrombin time >15s; if use of any direct oral anticoagulant within the last 48 hours; if use of heparin/heparinoid within the last 24 hours
  • Ischemic stroke or myocardial infarction in previous 3 months
  • Previous intracranial hemorrhage, active internal bleeding (gastrointestinal or urinary tract hemorrhage) in previous 3 months
  • Severe, uncontrolled hypertension (systolic blood pressure >185mmHg or diastolic blood pressure >110mmHg)
  • Baseline blood glucose \<50mg/dl or >400mg/dl
  • Baseline count \<100,000/μL
  • Undergoing hemodialysis or peritoneal dialysis; known severe renal insufficiency with \<30mL/min or serum creatinine >220mmol/L (2.5mg/dL)
  • Known severe, life-threatening allergy (more severe than skin rash) to contrast agents
  • Patients with acute stroke within the first 48 hours after percutaneous cardiac, cerebrovascular interventions and major surgery
  • Known diagnosis or clinical suspicion of cerebral vasculitis
  • Known diagnosis or clinical suspicion of endocarditis
  • Pregnancy or lactating;
  • Other serious, advanced or terminal illness with less than 6 months
  • Current participation in any study that may confound outcome assessment of the study
  • Any condition that, in the judgement of the investigator, is inappropriate for participation in the trial or could impose hazards to the patient (e.g. inability to understand and/or follow the study procedures and/or follow-up due to mental disorders, cognitive or emotional disorders)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
316 participants (estimated)

Study arms

  • Experimental
    Interventional group

    Patients will receive intravenous Tenecteplase 0.25 mg/kg body-weight up to a maximum of 25mg before the interhospital transfer or the physician departure. A single bolus dose should be administered over 5-10 seconds based on patient weight. Transfer to ECCs or physician travelling for thrombectomy should be initiated immediately after Tenecteplase administration.

    Drug: Tenecteplase thrombolysis

  • No intervention
    Control group

    Patients will receive standard treatment and be directly transferred to ECCs or transfer physician for EVT according to Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023.

Interventions

  • DrugTenecteplaseStudies of TenecteplaseTenecteplase pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive intravenous Tenecteplase 0.25 mg/kg body-weight up to a maximum of 25mg before the transfer. A single bolus dose should be administered over 5-10 seconds based on patient weight. Transfer to ECCs for thrombectomy should be initiated immediately after Tenecteplase administration.

    Also known as: rhTNK-tPA

06

What researchers measure

Primary outcomes

  1. Dichotomized mRS of 0-2 vs. 3-6

    Dichotomized mRS of 0-2 vs. 3-6 at 90±7 days; modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death)

    Time frame: 90±7 days

Secondary outcomes

  1. Ordinal mRS score

    Ordinal mRS score at 90 (±7) days; modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death)

    Time frame: 90 (±7) days

  2. Dichotomized mRS of 0-1 vs. 2-6

    Dichotomized mRS of 0-1 vs. 2-6 at 90 (±7) days

    Time frame: 90 (±7) days

  3. Dichotomized mRS of 0-3 vs. 4-6

    Dichotomized mRS of 0-3 vs. 4-6 at 90 (±7) days

    Time frame: 90 (±7) days

  4. Early dramatic clinical response rate

    Early dramatic clinical response rate at 24 (±12) h, defined as a NIHSS score of 0 or 2 or NIHSS drop of ≥8 from baseline

    Time frame: 24 (±12) hours

  5. Arterial recanalization during interhospital transfer

    Arterial recanalization during interfacility transfer, evaluated with the angiography (CTA/MRA/first run of DSA) at ECC

    Time frame: At ECC before thrombectomy or physician-arrival

  6. Successful reperfusion

    Successful reperfusion at end-of-procedure angiography, defined as expanded Treatment in Cerebral Infarction (eTICI) score of 2b, 2c, or 3 on angiography

    Time frame: At end-of-procedure angiography (up to 15 minutes)

  7. First pass excellent reperfusion

    First pass reperfusion defined as eTICI 2c or greater after the first thrombectomy pass

    Time frame: Immediately after the thrombectomy

  8. Arterial recanalization

    Arterial recanalization at 24(±12)h, evaluated with CTA/MRA

    Time frame: 24(±12) hours

  9. EQ-5D-5L

    Score on the EQ-5D-5L at 90 (±7) days;(EQ-5D-5L: Minimum Score 5, Maximum score 25, lower scores mean a better quality of life).

    Time frame: 90 (±7) days

Other outcomes

  1. Symptomatic intracranial hemorrhage (sICH)

    Incidence of sICH (Heidelberg criteria) measured at 36 hours

    Time frame: 36 hours

  2. Parenchymal hematoma type 2 (PH2)

    Incidence of PH2 at 36h

    Time frame: 36 hours

  3. All cause mortality

    All-cause mortality up to 90 (±7) days.

    Time frame: 90 (±7) days.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's planned 23 months is below that.

Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Oct 2, 2025
StartActual
Jan 20, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07203625
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Jan 20, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 19, 2026

Study contacts

Junwei Hao, MD
Contact
haojunwei@vip.163.com
01083198277
Gaoting Ma, MD
Contact
demo_doctor@163.com
01083198082
Junwei Hao, MD
principal investigator · Xuanwu Hospital, Beijing

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion